Equity Details
Price & Market Data
Price: $3.69
Daily Change: +$0.075 / 2.03%
Daily Range: $3.42 - $3.82
Market Cap: $6,114,057
Daily Volume: 26,417
Performance Metrics
1 Week: -18.03%
1 Month: -38.38%
3 Months: -57.21%
6 Months: -93.91%
1 Year: -81.12%
YTD: -88.71%
About BioAtla, Inc. (BCAB)
Get insights into BioAtla, Inc. (BCAB)'s financial health. With a price of 3.69, the stock shows a +$0.075 / 2.03% daily change. Its market cap is 6,114,057. Detailed performance for 1-month (-38.38%) and 52-week (-81.12%) periods are crucial.
Company Details
Employees: 41
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
